UK authority in new home by year end:
This article was originally published in Clinica
Executive Summary
Moves are being taken to ensure that the staff of the medical devices and pharmaceutical sections of the UK's Medicines and Healthcare products Regulatory Agency, the MHRA, are on the same or adjacent sites by the end of the year. That was what Professor Kent Woods told the industry when he spoke at the 12th Annual Conference of the Association of British Health-Care Industries on June 24. He added that the regulatory agency will also "clearly need to remain financially solvent". The former Medical Devices Agency was due to move out of its Elephant & Castle, south London premises anyway, due to the lease expiring this year, but the merger between the device and pharmaceutical regulatory authorities and synergies between the two sectors has underlined the wisdom of keeping the two units together.
You may also be interested in...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.